Headache News and Research

Latest Headache News and Research

FDA approves Abstral drug for treatment of breakthrough pain in cancer patients

Orexo AB announces today that its partner ProStrakan Group plc has received approval from the US Food and Drug Administration for Abstral. Abstral is licensed for the treatment of breakthrough pain in cancer patients, 18 years of age and older, who are already receiving, and are tolerant to, opioid analgesics for their underlying persistent cancer pain.

10 Jan 2011

Positive results form INX-189 Phase 1b trial against hepatitis C virus

Inhibitex, today reported positive preliminary interim safety and antiviral data from the first two monotherapy cohorts of its ongoing Phase 1b clinical trial of INX-189, an oral NS5b nucleotide inhibitor being developed to treat chronic infections caused by hepatitis C virus.

10 Jan 2011

Abstral transmucosal tablets receive FDA approval, may help manage pain in cancer patients

The U.S. Food and Drug Administration today approved Abstral transmucosal tablets to manage breakthrough pain for adults with cancer.

9 Jan 2011

NovaDel receives $500,000 milestone payment from Akrimax in connection with NitroMist agreement

NovaDel Pharma Inc. today announced that it has received a $500,000 milestone payment from Akrimax Pharmaceuticals. The milestone payment was received in connection with the license and distribution agreement, dated October 27, 2009, between NovaDel Pharma Inc. and Mist Acquisition, LLC, an affiliate of Akrimax Pharmaceuticals.

7 Jan 2011

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Bristol-Myers Squibb Company, and AstraZeneca today announced that KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release), approved by the U.S. Food and Drug Administration (FDA) on November 5, 2010, is now available by prescription in pharmacies across the United States.

7 Jan 2011

Dendreon provides U.S. commercialization and European strategy updates for PROVENGE

Dendreon Corporation today announced several updates regarding the U.S. commercialization of PROVENGE® (sipuleucel-T), the European strategy for PROVENGE, and progress on its pipeline.

7 Jan 2011

Pharmasset reports positive data from PSI-7977 and PSI-938 HCV clinical programs

Pharmasset, Inc., announced today positive data from interim analyses of two of its clinical programs: the HCV genotype 2 or 3 (GT2/3) arm of the PSI-7977 Phase 2b trial and the 14 day PSI-938 monotherapy cohort of the dual nucleotide study.

7 Jan 2011

Researchers identify genetic mutation responsible for acromegaly disease

An international research team, spearheaded by scientists from the London School of Medicine and Dentistry, has identified the genetic mutation responsible for a disease known as "gigantism" or acromegaly.

7 Jan 2011

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

Genentech, Inc., a member of the Roche Group, today announced that the United States Food and Drug Administration has extended the ACTEMRA (tocilizumab, RoACTEMRA in the European Union) label to include inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical response in adult patients with moderately to severely active rheumatoid arthritis, when given in combination with methotrexate.

6 Jan 2011

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene International Sàrl announced regulatory submissions for its blood cancer therapies REVLIMID (lenalidomide) and ISTODAX (romidepsin).

5 Jan 2011

Clinical Decision Support Systems help reduce unnecessary CT and MRI scans

Researchers from Virginia Mason Medical Center in Seattle, WA, have found that clinical decision support systems can help reduce inappropriate medical imaging, including unnecessary computed tomography (CT) and magnetic resonance imaging (MRI) scans, according to a study in the January issue of the Journal of the American College of Radiology (www.jacr.org).

4 Jan 2011

Combat-related PTSD associated with longer-term physical, emotional and cognitive symptoms

Combat-related post-traumatic stress disorder (PTSD) symptoms appear to be associated with longer-term physical (headache, tinnitus), emotional (irritability) and cognitive (diminished concentration or memory) symptoms, according to a report in the January issue of Archives of General Psychiatry, one of the JAMA/Archives journals. Conversely, concussion/mild traumatic brain injuries (MTBI) do not appear to have long-term negative effects on troops.

4 Jan 2011

Tips to prevent a hangover

Dr. Andrew Yacht, director of the division of general medicine and vice chair of medicine for education at Maimonides Medical Center in New York City said, “Alcohol clearly causes hangovers, but why it causes hangovers isn’t very well understood…Part of the suspected cause is dehydration and an electrolyte and hormonal imbalance. Some of the symptoms may be caused by low blood sugar. Or, it may be that the direct toxic effects of alcohol are causing the symptoms.”

2 Jan 2011

Researchers to identify gene variants that cause ischemic stroke

Researchers from the University of Maryland School of Medicine are coordinating an international team of scientists working to identify genes or gene variants that may make a person more likely to have a particular type of stroke called an ischemic stroke.

30 Dec 2010

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

Centocor Ortho Biotech Inc. announced today that it has filed a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) requesting the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy.

29 Dec 2010

Hangover tips for the festive season!

A bad hangover usually comes with a variety of symptoms like headaches, fatigue, upset stomach, sweating, nausea, bad taste in the mouth excessive thirst, sensitivity to light etc. This is mainly due to the diuretic effects of alcohol that leaves one dehydrated.

28 Dec 2010

Cephalon receives second FDA Complete Response Letter for NUVIGIL sNDA

Cephalon, Inc. today announced that the company received a second Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the supplemental new drug application (sNDA) for NUVIGIL(R) (armodafinil) Tablets [C-IV] for the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel. In its letter to the company, the FDA reiterated its previously stated concerns regarding the NUVIGIL sNDA.

28 Dec 2010

MigreLief releases safe, proven effective supplement for children with migraines

MigreLief, the first name in migraine prevention, releases a safe and proven effective supplement for children of all ages: Children's MigreLief.

24 Dec 2010

Zogenix announces underwriters partial exercise of over-allotment option in initial public offering

Zogenix, Inc. announced today that the underwriters of its recently completed initial public offering of common stock have partially exercised their option to purchase shares of common stock from Zogenix to cover over-allotments. The sale of additional shares is expected to close on December 27, 2010.

23 Dec 2010

USAID official discusses agency's efforts to address cholera in Haiti

A USAID official said Tuesday that potential violence following the release of Haiti's final presidential election results could interfere with efforts to contain the country's cholera epidemic, CBC News reports. "What we all worry about is if there is violence again and it disrupts for a couple of days," said Mark Ward, acting director of USAID's Office of U.S. Foreign Disaster Assistance. "That's my biggest headache right now," he added.

23 Dec 2010

Headache News and Research

Latest Headache News and Research

FDA approves Abstral drug for treatment of breakthrough pain in cancer patients

Positive results form INX-189 Phase 1b trial against hepatitis C virus

Abstral transmucosal tablets receive FDA approval, may help manage pain in cancer patients

NovaDel receives $500,000 milestone payment from Akrimax in connection with NitroMist agreement

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Dendreon provides U.S. commercialization and European strategy updates for PROVENGE

Pharmasset reports positive data from PSI-7977 and PSI-938 HCV clinical programs

Researchers identify genetic mutation responsible for acromegaly disease

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Clinical Decision Support Systems help reduce unnecessary CT and MRI scans

Combat-related PTSD associated with longer-term physical, emotional and cognitive symptoms

Tips to prevent a hangover

Researchers to identify gene variants that cause ischemic stroke

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

Hangover tips for the festive season!

Cephalon receives second FDA Complete Response Letter for NUVIGIL sNDA

MigreLief releases safe, proven effective supplement for children with migraines

Zogenix announces underwriters partial exercise of over-allotment option in initial public offering

USAID official discusses agency's efforts to address cholera in Haiti

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Headache News and Research

Latest Headache News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in